BC
BCRX icon

Bayforest Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bayforest Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
27,728
+27,725
+924,167% +$251K 0.26% 82
2026
Q1 		$29 Sell
3
-8,476
-100% -$65.8K ﹤0.01% 877
2025
Q4 		$66.1K Sell
8,479
-61,552
-88% -$445K 0.05% 546
2025
Q3 		$532K Sell
70,031
-23,691
-25% -$197K 0.25% 123
2025
Q2 		$840K Buy
+93,722
New +$873K 0.37% 63

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Bayforest Capital's BCRX Position: Q2 2026 in Review

Bayforest Capital increased its BioCryst Pharmaceuticals (BCRX) stake by 924,167% in Q2 2026, buying an estimated $251K and bringing the position to 27,728 shares worth $277K. The position accounts for 0.26% of the portfolio, ranked #82.

Bayforest Capital first reported a position in BCRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $840K in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Bayforest Capital held 27,728 shares of BioCryst Pharmaceuticals worth $277K as of Q2 2026.
  • Bayforest Capital bought 27,725 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $251K.
  • BioCryst Pharmaceuticals made up 0.26% of Bayforest Capital's portfolio in Q2 2026, its #82 holding.
  • Bayforest Capital first reported a position in BioCryst Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Bayforest Capital's BioCryst Pharmaceuticals position peaked at $840K in Q2 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.